Teva Pharmaceuticals has reached a settlement with Cuyahoga and Summit counties of Ohio to settle claims in the Opioid addiction lawsuit. Under the terms of the settlement, Teva will provide buprenorphine-naloxone (sublingual tablets), known by the brand name Suboxone®, valued at $25...
Teva Pharmaceutical has entered into a settlement with the State of Oklahoma over the company's marketing of Opioid drugs. Although Teva has not admitted any wrongdoing, it has agreed to pay a fine of $85 million to settle all outstanding claims against...
Foamix Pharmaceuticals Ltd. received U.S. Food and Drug Administration (FDA) approval for its  AMZEEQTM (minocycline) topical foam, 4%. AMZEEQ, provides treatment for inflammatory lesions caused by non-nodular moderate to severe acne vulgaris in adults and pediatric patients (age 9 and older). This...
Teva Pharmaceuticals USA, announced that the Food and Drug Administration (FDA) has approved an auto-injector device for AJOVY® (fremanezumab-vfrm) injection for migraines. “The approval of the AJOVY auto-injector is another important step forward for Teva and the migraine community,”...
Teva Pharmaceutical received excellent news today, when it was reported the company had reached a tentative agreement with the State of Ohio for its part in the Opioid crisis. The settlement was for $10 million, a sum much below the expectations of...
2021 business outlook:Revenues are expected to be $16.4 - $16.8 billion (2020 actual results include ~$240 million in revenues from generic products in Japan divested on February 1, 2021, along with a manufacturing site)Non-GAAP EPS is expected to be $2.50 - $2.70Free...
Haifa, Israel, October 3, 2021 – Elbit Systems Ltd. (NASDAQ: ESLT and TASE: ESLT) ("Elbit Systems") announced today that its subsidiaries, Beyeonics Surgical Ltd. (“Beyeonics Surgical”) and Beyeonics Vision Ltd. (“Beyeonics Vision”), concluded a financing round in an aggregate amount of $36 million. The financing round is...
Teva Pharmaceutical Industries Ltd reported third-quarter results that were better than expected by analysts. It also appointed Eli Kalif as Executive Vice President and Chief Financial Officer. Revenues in the third quarter of 2019 were $4,264 million,...
Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of Tarceva®1 (erlotinib) tablets, 100 and 150 mg, in the U.S. Erlotinib Tablets are a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung...
Teva, once the flagship company of the Israeli economy, has had more woes than the prophet Job. Despite its many problems, Teva still has a strong core business and hopes that by cutting enough expenses from its operations it can become profitable...